Skip to main navigation
  • >Newsroom
    • Latest News
    • Archives
    • Media Inquiries
  • >Careers
    • Join Our Team
    • Job Opportunities
  • >Contact
    • General Inquiries
Search
Twitter LinkedIn
NexImmune, Inc. NexImmune, Inc.
  • Our Technology
    • Our Technology
      • AIM™ NT Platform
      • AIM™ ACT Adoptive Cellular Therapy
      • AIM™ INJ Direct Injection
      • Abstracts and Publications
    • Our Pipeline
      • Overview
    • Our Company
      • Overview
      • Leadership
      • Board of Directors
      • Scientific Advisors
      • Autoimmune and Infectious Diseases SAB
    • Investors
      • Overview
      • Press Releases
      • Events and Presentations
      • Financials and Filings
      • Stock Information
      • Corporate Governance
      • Email Alerts
      • Contact
  • Our Pipeline
    • Our Technology
      • AIM™ NT Platform
      • AIM™ ACT Adoptive Cellular Therapy
      • AIM™ INJ Direct Injection
      • Abstracts and Publications
    • Our Pipeline
      • Overview
    • Our Company
      • Overview
      • Leadership
      • Board of Directors
      • Scientific Advisors
      • Autoimmune and Infectious Diseases SAB
    • Investors
      • Overview
      • Press Releases
      • Events and Presentations
      • Financials and Filings
      • Stock Information
      • Corporate Governance
      • Email Alerts
      • Contact
  • Our Company
    • Our Technology
      • AIM™ NT Platform
      • AIM™ ACT Adoptive Cellular Therapy
      • AIM™ INJ Direct Injection
      • Abstracts and Publications
    • Our Pipeline
      • Overview
    • Our Company
      • Overview
      • Leadership
      • Board of Directors
      • Scientific Advisors
      • Autoimmune and Infectious Diseases SAB
    • Investors
      • Overview
      • Press Releases
      • Events and Presentations
      • Financials and Filings
      • Stock Information
      • Corporate Governance
      • Email Alerts
      • Contact
  • Investors
    • Our Technology
      • AIM™ NT Platform
      • AIM™ ACT Adoptive Cellular Therapy
      • AIM™ INJ Direct Injection
      • Abstracts and Publications
    • Our Pipeline
      • Overview
    • Our Company
      • Overview
      • Leadership
      • Board of Directors
      • Scientific Advisors
      • Autoimmune and Infectious Diseases SAB
    • Investors
      • Overview
      • Press Releases
      • Events and Presentations
      • Financials and Filings
      • Stock Information
      • Corporate Governance
      • Email Alerts
      • Contact
  • Our Technology
    • AIM™ NT Platform
    • AIM™ ACT Adoptive Cellular Therapy
    • AIM™ INJ Direct Injection
    • Abstracts and Publications
  • Our Pipeline
    • Overview
  • Our Company
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Autoimmune and Infectious Diseases SAB
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • Email Alerts
    • Contact
  • Newsroom
    • Latest News
    • Archives
    • Media Inquiries
  • Careers
    • Join Our Team
    • Job Opportunities
  • Contact
    • General Inquiries

Investors: SEC Filing Details

SEC Filing Details

Document Details

Form
10-Q
Filing Date
Nov 14, 2022
Document Date
Sep 30, 2022
Form Description
Quarterly report which provides a continuing view of a company's financial position
Filing Group
Quarterly Filings
Company
NexImmune, Inc.
Issuer
NexImmune, Inc.

Filing Formats

iXBRL
View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
XML - XBRL INSTANCE DOCUMENT
  • Overview
  • Press Releases
  • Events and Presentations
  • Financials and Filings
  • Stock Information
  • Corporate Governance
  • Email Alerts
  • Contact
  • Our Technology
  • AIM™ NT Platform
  • AIM™ ACT Adoptive Cellular Therapy
  • AIM™ INJ Direct Injection
  • Abstracts and Publications
  • Our Pipeline
  • Overview
  • Careers
  • Join Our Team
  • Job Opportunities
  • Our Company
  • Overview
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Autoimmune and Infectious Diseases SAB
  • Newsroom
  • Latest News
  • Archives
  • Media Inquiries
  • Contact
  • General Inquiries
  • Investors
  • Overview
  • Press Releases
  • Events and Presentations
  • Financials and Filings
  • Stock Information
  • Corporate Governance
  • Email Alerts
  • Contact
About Us

NexImmune is a rapidly growing leader in the emerging field of antigen-directed immunotherapies. We are developing a novel technology platform with broad application across multiple disease areas.

Our Vision is to conquer cancer and life-threatening immune-mediated conditions by directing natural, disease-specific immune responses.

NexImmune, Inc. footer logo

9119 Gaither Road
Gaithersburg, MD 20877

Twitter LinkedIn

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to NexImmune, its subsidiaries or affiliates. No use of any NexImmune trademark, trade name, or trade dress in this site may be made without the prior written authorization of NexImmune, except to identify the product or services of the company.

© NexImmune, Inc.. All Rights Reserved. 2023

  • Terms of Use
  • Privacy
  • Cookies